#NSCLC

[mdnewsline1]

Major Breakthrough: Pembrolizumab Shows 5-Year Survival Benefit in NSCLC Patients!

Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)! 📊 With a 5-year survival rate of 26.9%, this treatment is changing the game for NSCLC patients. Learn how factors like PD-L1 expression, age, and ECOG-PS impact survival. Read the full analysis now! 🏥🔬

 Read the full study now: https://mdnewsline.com/five-year-survival-in-nsclc-patients-treated-with-first-line-pembrolizumab/

For more insights visit: https://mdnewsline.com/

[healthcaretechnologynews]

Biomarker driven segments of NSCLC - Yet to saturate with new approvals

Industry experts think that NSCLC space is rushed with so many approvals, yet it is a hot space for researchers, as NSCLC market has huge potential and even 1% market share is a piece of hot cake for the investors.

Currently, there are a total of 5 FDA-approved TKIs for frontline treatment in EGFR- positive NSCLC.

Though, recent data on frontline Osimertinib confers the greatest progression-free survival (PFS) advantage for patients with EGFR-positive non–small cell lung cancer (NSCLC)

Experts indicated that they would look forward to the novel approaches that are trying to enhance the activity of Osimertinib by targeting other oncogenic pathways in combination with anti-EGFR therapy.

Write to us at enquire@grgonline.com to learn how GRG Health is helping clients gather more in-depth market-level information on such topics.

Chemotherapy is backbone to treat many types of cancers, and research continues to find new chemotherapy regimens in combination with novel drugs. Over a decade, NSCLC space has evolved immensely.

Even though NSCLC space has been bifurcated into many biomarkers driven patients’ segment with specific approval in these segments, still in upcoming years we will see more approvals in the space. Industry experts think that this space is rushed with so many drugs, yet it is a hot space for researchers, as NSCLC is a huge market and even a single percent market share is a piece of hot cake for the investors.

Currently there are a total of 5 FDA-approved TKIs for frontline treatment of EGFR- positive NSCLC. These include erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), Dacomitinib (Vizimpro), and Osimertinib (Tagrisso).

We have seen a lot of exciting data over the past couple years with regard to these agents as monotherapy or in combination. Despite the sequential efficacy of these FDA-approved EGFR TKIs, frontline Osimertinib confers the greatest progression-free survival (PFS) advantage for patients with EGFR-positive non–small cell lung cancer (NSCLC) recently.

Therefore, we still expect to see several studies moving forward with results reported out in the coming years. We expect an emergence of new biomarker driven segments also (for e.g., Novel combinations, certainly targeting VEGF or MET).

There are exciting ongoing studies targeting MET following progression on Osimertinib. Experts indicated that they would look forward to the novel approaches that are trying to enhance the activity of Osimertinib by targeting other oncogenic pathways in combination with anti-EGFR therapy.

Visit our website now: https://www.grgonline.com/

[healthcareporium]

Innovating Lung Cancer Care: Antibody-Drug Conjugates Lead the Way

The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate…

[medsforcancer8]

buy non-small cell lung cancer

[butchlifeguard]

no way y'all aren't looking these up on the job

[industryexperts]

(via Global Lung Cancer Therapeutics Market | Trends, Forecast 2024-2030)

The lung cancer therapeutics market in 2024 is dominated by the non-small cell lung cancer (NSCLC) type, which holds an estimated 85.3% share due to its high prevalence and the development of targeted therapies and immunotherapies. These advancements specifically target genetic mutations such as EGFR, ALK, and ROS1, providing personalized treatment options and improving patient outcomes with immune checkpoint inhibitors like pembrolizumab and nivolumab. Conversely, the small cell lung cancer (SCLC) segment is anticipated to register the fastest CAGR of 11% during the forecast period 2024-2030, driven by increasing smoking rates and greater awareness of available treatments. While traditional SCLC therapies primarily consist of chemotherapy and radiotherapy, the introduction of new treatments like immune checkpoint inhibitors is beginning to improve survival rates, leading to a surge in global demand for lung cancer therapeutics.

[garnerbio]

PRESERVING THE PAST, DIAGNOSING THE FUTURE: FFPE BLOCKS IN CANCER TISSUE RESEARCH

FFPE tissue preservation involves two critical steps: fixation and embedding. The fixation process begins by immersing the tissue sample in formalin, a formaldehyde solution, which cross-links proteins and stabilizes cellular structures. This step is crucial as it prevents the degradation of tissue and preserves morphological details at the microscopic level

[perpetualseahorse]

Wtf tumblr

[futuretonext]

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide. 

[usnews23]

Perioperative Immunotherapy: A Promising Advancement in Early NSCLC Treatment

In recent years, the field of oncology has witnessed significant advancements in the treatment of various cancers, including non-small cell lung cancer (NSCLC). One such promising development is the utilization of perioperative immunotherapy, which has shown the potential in improving event-free survival (EFS) for early-stage NSCLC patients. In this comprehensive article, we explore the impact of…

[reasonsforhope]

"Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

The UK has six sites, located in England and Wales, with the first UK patient to receive the vaccine having their initial dose on Tuesday [August 20, 2024].

Overall, about 130 patients – from early-stage before surgery or radiotherapy, to late-stage disease or recurrent cancer – will be enrolled to have the jab alongside immunotherapy. About 20 will be from the UK.

The jab uses messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers.

The aim is to strengthen a person’s immune response to cancer while leaving healthy cells untouched, unlike chemotherapy.

“We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer,” said Prof Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which is leading the trial in the UK.

“It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them. This technology is the next big phase of cancer treatment.”

Janusz Racz, 67, from London, was the first person to have the vaccine in the UK. He was diagnosed in May and soon after started chemotherapy and radiotherapy.

The scientist, who specialises in AI, said his profession inspired him to take part in the trial. “I am a scientist too, and I understand that the progress of science – especially in medicine – lies in people agreeing to be involved in such investigations,” he said...

“And also, I can be a part of the team that can provide proof of concept for this new methodology, and the faster it would be implemented across the world, more people will be saved.”

Racz received six consecutive injections five minutes apart over 30 minutes at the National Institute for Health Research UCLH Clinical Research Facility on Tuesday.

Each jab contained different RNA strands. He will get the vaccine every week for six consecutive weeks, and then every three weeks for 54 weeks.

Lee said: “We hope adding this additional treatment will stop the cancer coming back because a lot of time for lung cancer patients, even after surgery and radiation, it does come back.” ...

“We hope to go on to phase 2, phase 3, and then hope it becomes standard of care worldwide and saves lots of lung cancer patients.”

The Guardian revealed in May that thousands of patients in England were to be fast-tracked into groundbreaking trials of cancer vaccines in a revolutionary world-first NHS “matchmaking” scheme to save lives.

Under the scheme, patients who meet the eligibility criteria will gain access to clinical trials for the vaccines that experts say represent a new dawn in cancer treatment."

-via The Guardian, May 30, 2024

[mindblowingscience]

The mRNA revolution continues. Just a few years after mRNA vaccines proved their efficacy against COVID-19, scientists are now turning their attention to lung cancer. The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first of its kind and has entered phase 1 clinical trials in seven countries, including the United States and the United Kingdom. This vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

Continue Reading.

[justkidneying]

Shit in the Lungs

I'm gonna give some examples of what you can give your characters if you want them to have a little cough, and one example of a disease that you probably don't want to use.

Tuberculosis: this is that classic one when you're watching a Western and someone coughs up blood into a hankie.

caused by a mycobacterium and can be found in about 1/4 of the world's population (but only 5-10% of those people will ever become symptomatic)

one of the most interesting features of this disease is the fact that someone can get it and not have an active infection for DECADES (but don't worry, they can't spread it either)

the immune system can't kill it to well, so instead it makes these nice granulations around it in the lungs, which is called caseating necrosis (looks like soft cheese - but tastes horrible)

TB can spread to the kidneys (pissing pus), spine, and brain (meningitis). The last one causes fever, headache, coma, and then you die

for regular TB in the lungs: fever, night sweats, weight loss (that's why it was once called consumption), coughing, hemoptysis (coughing up blood), chest pain, tiredness, and malaise

Pneumonia: this is really broad, but in general means the lungs are filling with fluid and you can't breathe

this can be caused by several viruses, fungi, and bacteria. Go look up the specific cause you want, or maybe I'll cover it in the next decade

you have these little air sacs (called alveoli) in your lungs, and if they are filled with crap, they can't exchange CO2 and O2 with your blood and the atmosphere

basic symptoms are coughing, chest pain, fever, chills, nausea, fatigue, headache

there's also walking pneumonia, in which you don't feel shitty enough to stay home so you're out and about while your lungs fill with fluid. usually pretty mild

Lung Cancer: this is the cancer with the highest mortality, and is more common in people who smoke or work in certain manufacturing plants

this can present similar to other types of lung diseases

main symptoms include chest pain, weight loss, tiredness, coughing, hemoptysis, shortness of breath, and constant lung infections

the main types are small-cell and non-small-cell, with the latter usually having a worse prognosis. All stages combined, NSCLC has a 5-year survival rate of about 28%, while SCLC has one of about 7%

Finally, the one I've seen in fics but in a context that doesn't make sense: cystic fibrosis. This is a genetic mutation, guys (CFTR gene to be specific). You can't catch this and it isn't caused by a microorganism. People with this disease produce especially thick mucus, leading to an inability to clear the lungs (plus some stuff with the small intestines, pancreas, and kidneys). They also have very salty sweat which is actually a way people can get diagnosed (parents will kiss their kids foreheads and taste the salt, lol). Because of the lung issues, people with CF will be at risk for certain and frequent lung infections. There is no cure and in the USA they usually live to be about 50 years old.

I hope I have given you guys some good info, feel free to ask questions in the comments if there is something I did not touch on. I just hope I never see someone "catching" CF again (please <3)

[ihnmaims]

My mother doesn't have only one, but two — that's right, count them, two — different types of lung cancer. On one side of her chest, she has second-stage SCLC. On the other side of her chest, she has third-stage NSCLC. One of them has spread to her lymph nodes but because I've been struggling to assimilate an absolutely overwhelming amount of information since the situation started, I don't remember if it's the SCLC or NSCLC that's managed to travel there.

The SCLC is in fact the more severe of the two, even though it's earlier in its development than the NSCLC, because it is a much more aggressive and dangerous type of cancer.

She will be receiving radiation therapy daily, and additionally, she will be receiving chemotherapy... weekly, I think. Or maybe multiple times a week. I don't really remember. I am accompanying her to all of her appointments and I am trying to soak up the things that I learn from the doctors and the nurses like a sponge, but I truly believe that it is impossible for only one singular individual to absorb and retain so much information.

And it is, indeed, just one singular individual. Me. I'm not exaggerating. My mother was already a ditzy woman with the attention span of a fucking fruit fly before drugs and the overall stress of the situation sent her out of her mind, and as for my sack of shit of a "father," well... Suffice to say that he has chosen to remain uninvolved. He decidedly does not give a flying fuck about my mother and he never has — this will not be the thing that makes him start. Actually, to be honest, he seems eager to watch her die.

So it's me scheduling things for her, it's me taking her to the things that I've scheduled for her, it's me talking to the doctors and nurses for her, it's me asking them the important questions for her and remembering the important answers for her. Or trying to. I have a dissociative disorder which means that I have impaired memory, and I'm not new to medicine but I'm new to the subject of cancer, specifically; stepping into the field of oncology feels like stepping into a strange and unfamiliar world where there are people suffering to a degree that I never knew was possible. The sheer scale of everything that's being thrown straight at me so suddenly after a lifetime of being sheltered from all of it is insane. I've never known anyone who has had cancer before, see.

I'll be brutally honest: since her cancers are stage two and stage three, they aren't necessarily terminal, but because she's aging significantly and her health has been declining for decades, her chances of survival still aren't amazing. The oncologist she's seeing said that he's "cautiously optimistic" that "with timely treatment," she has "potential" to live 1-5 more years. He said that she shouldn't feel obligated to spend the remainder of her time making herself sick with these therapies, and can consider foregoing the treatment to focus on receiving high-quality end-of-life care instead. He sounded rather sure of her having a short life expectancy. Much shorter than I originally dared to let myself think.

She's a trooper, though. At least, she's trying to be. She started treatment today. There's something called a port that's been surgically installed into her neck. I'm not sure of the exact function of the port, even though it's been explained to me, but it's to make administering intravenous medicine easier and more convenient, I know that.

When one of her nurses accessed her port today, she bled and she cried. She said she was alright but I could tell that she was lying to try to impress me. I held her hand and she almost crushed my fingers. We're going back tomorrow. I'm wondering, will I have to watch her bleed and cry while I make an unsuccessful attempt at consoling her then, too? Will that become a part of our daily routine? From now on, will I be starting my morning by watching the woman I love the most suffer so immensely?

We've been at the hospital almost nonstop for the last two weeks, seeking consultations, tests, test results, etc. But she only officially began treatment today and I'm already tired. I'm tired of seeing her hurt. I'm tired of life being so fucking unfair to her. She doesn't deserve to be so sick. And, on a somewhat more selfish note, I'm tired on a purely physical level too. Come hell or high water, I will be with her every step of the way, but by God... daily trips to the hospital that are 2-8 hours long are taking a lot out of me and my incredibly broken body. Obviously, her life's much more important than my disability, so I can't complain too much. Just know that it's very demanding and very taxing and taking quite the toll.

It's an awful journey to embark on, but she's not dragging me along with her — I'm here with her because want to be here with her. I insist. It's my responsibility to take care of those that I love, even though I'm afraid and, to be frank, incompetent. I'm faking my confidence and pretending to know what I'm doing as a means of comforting her, because the truth behind how I feel would break her heart: I'm not hopeful at all. The future looks as bleak to me as it must feel to her.

Normally, I think it's pointless to be preemptively sad about something that hasn't happened yet, and I think it's pointless to preemptively grieve something that hasn't been lost yet. But I'm having a hard time abiding those principles now. When "the end" has been defined with such clarity, and mapped out plainly for me to see, how am I supposed to stop myself from mourning? I know what's coming. I know she's dying.

I can't stop it. I can't help her in a way that actually matters. I can only make sure that when she does die, she's not lonely.

I love her a lot. I don't think I'll be active on here much anymore.

[mezzopieno-news]

APPROVATO IL FARMACO PER LA CURA DEL CARCINOMA POLMONARE

La Food and Drug Administration ha approvato il nuovo trattamento adiuvante dopo la resezione del tumore in pazienti con carcinoma polmonare non a piccole cellule (NSCLC) ALK positivo. Questo sottotipo di cancro del polmone è caratterizzato dalla presenza di una fusione o riarrangiamento genico che iperattiva la proteina ALK ed è una mutazione che rappresenta circa l’85% dei casi di carcinoma polmonare, il cui 5%risulta essere ALK positivo.

Il farmaco alectinib ha dimostrato la riduzione del rischio di recidiva della malattia o di morte rispetto alla chemioterapia ad un tasso del 76%, definito dai ricercatori “senza precedenti“, migliorando significativamente lo standard di cura per le persone affette da carcinoma polmonare ALK positivo in fase precoce. “L’approvazione di Alecensa segna un momento cruciale per le persone a cui è stato diagnosticato un tumore al polmone ALK positivo in fase iniziale che finora non potevano ricevere una terapia specifica”, ha dichiarato Ken Culver, direttore della ricerca e degli affari clinici di ALK Positive, Inc, una no-profit che si dedica a migliorare l’aspettativa dei pazienti in tutto il mondo. “Questi pazienti, che in genere ricevono la diagnosi in giovane età, vanno spesso incontro a recidive e hanno un rischio maggiore di sviluppare metastasi cerebrali rispetto a quelli affetti da altri tipi di NSCLC. Ora, con questo significativo progresso, è più importante che mai che tutte le persone a cui è stato diagnosticato un tumore al polmone in fase precoce si sottopongano al test per ALK e altri biomarcatori raccomandati per ricevere il trattamento più appropriato per loro”.

___________________

Fonte: Food and Drug Administration; ALK Positive Inc; foto di Anna Shvets

VERIFICATO ALLA FONTE | Guarda il protocollo di Fact checking delle notizie di Mezzopieno

BUONE NOTIZIE CAMBIANO IL MONDO | Firma la petizione per avere più informazione positiva in giornali e telegiornali

Se trovi utile il nostro lavoro e credi nel principio del giornalismo costruttivo non-profit | sostieni Mezzopieno